Overview
VRCA market data
Price History
VRCA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.68 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.59 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -48.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.28 – $9.82 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $86.9M · P/B 3.19 · P/S 2.34.
Company News
8-K filing — Verrica Pharmaceuticals Inc. (VRCA)SEC EDGAR · Aug 6, 2026, 8:34 PM
Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M EstimateBenzinga · Aug 6, 2026, 8:08 PM
Verrica Pharmaceuticals Grants Medomie Pharma Rights To Seek Israeli Regulatory Approval For And To Distribute YCANTH For The Treatment Of Molluscum Contagiosum With Up To $8.2M In MilestonesBenzinga · Jul 21, 2026, 12:07 PM
Verrica Pharmaceuticals Doses First U.S. Patient In Second Pivotal Clinical Trial COVE-3Benzinga · Jun 22, 2026, 12:15 PM
HC Wainwright & Co. Assumes Verrica Pharmaceuticals at Buy, Announces Price Target of $12Benzinga · May 26, 2026, 10:51 AM